Please assess the completion status of the following clinical trial:

Trial Title: Double-blind Comparative Study of SYR-472

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. The participant is an outpatient.~2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.~Exclusion Criteria:~1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.（e.g., subjects who require hospitalization or subjects who were hospitalized within 24 weeks prior to the commencement of the observation period)~2. The participant is considered ineligible for the study for any other reason by the investigator or subinvestigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- SYR-472 100 mg (Type: EXPERIMENTAL): None
- Alogliptin 25 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).